ABCL
HEALTHCAREAbCellera Biologics Inc
$5.04+0.38 (+8.15%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ABCL Today?
No stock-specific AI insight has been generated for ABCL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.94$6.51
$5.04
Fundamentals
Market Cap$1.5B
P/E Ratio—
EPS$-0.49
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin-1.9%
Debt / Equity—
Trading
Volume7.7M
Avg Volume (10D)—
Shares Outstanding305.3M
ABCL News
20 articles- Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 8, 2026
- Why AbCellera Biologics (ABCL) Is Up 16.1% After ABCL635 Trial Momentum Builds Ahead Of DataYahoo Finance·May 7, 2026
- AbCellera to Present at Upcoming Investor Conferences in May and June 2026Yahoo Finance·May 7, 2026
- JonesResearch Reiterates Buy on AbCellera Biologics (ABCL)Yahoo Finance·May 5, 2026
- A Look At AbCellera Biologics (ABCL) Valuation As It Prepares ABCL635 Phase 1 Interim UpdateYahoo Finance·May 2, 2026
- AbCellera Biologics Among 3 Promising Penny StocksYahoo Finance·May 1, 2026
- AbCellera Biologics Pivots to In-House Pipeline, Teases Q3 Phase II Data for ABCL635 Hot FlashesMarketbeat·Apr 24, 2026
- JonesResearch Initiates Coverage of AbCellera Biologics Inc. (ABCL)Yahoo Finance·Apr 20, 2026
- AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings CallYahoo Finance·Apr 20, 2026
- Is Jones Trading’s New Coverage of AbCellera (ABCL) Reframing Its Clinical-Stage Platform Narrative?Yahoo Finance·Apr 14, 2026
- AbCellera Biologics (ABCL) Committed to Leverage Differentiated Technology for Drug DiscoveryYahoo Finance·Apr 14, 2026
- AbCellera (ABCL): Among the Stocks That Could 10x Over the Next 5 YearsYahoo Finance·Apr 2, 2026
- AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026Yahoo Finance·Apr 1, 2026
- 3 Penny Stocks With Market Caps Under $19B To WatchYahoo Finance·Apr 1, 2026
- AbCellera Biologics Eyes Integrated Biotech Shift; ABCL635 Phase II Data Due in Q3 at ForumMarketbeat·Mar 18, 2026
- AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec SaysMarketbeat·Mar 4, 2026
- Why AbCellera (ABCL) Is Up 11.5% After Narrowing Losses And Expanding ESOP Share Capacity – And What's NextYahoo Finance·Feb 27, 2026
- AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75MYahoo Finance·Feb 26, 2026
- AbCellera Biologics Inc. Q4 2025 Earnings Call SummaryMoby·Feb 26, 2026
- AbCellera Biologics Inc (ABCL) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst ChallengesYahoo Finance·Feb 25, 2026
All 20 articles loaded
Price Data
Open$4.61
Previous Close$4.66
Day High$4.78
Day Low$4.59
52 Week High$6.51
52 Week Low$1.94
52-Week Range
$1.94$6.51
$5.04
Fundamentals
Market Cap$1.5B
P/E Ratio—
EPS$-0.49
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin-1.9%
Debt / Equity—
Trading
Volume7.7M
Avg Volume (10D)—
Shares Outstanding305.3M
About AbCellera Biologics Inc
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—